CLINICAL_TRIALS
trial_result
· 2018-04-11
Clinical Trial Update: Addressing Involuntary Movements in Tardive Dyskinesia [Phase 3]
Summary
Phase 3 trial update on addressing involuntary movements in tardive dyskinesia.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Auspex Pharmaceuticals, Inc. | Conditions: Tardive Dyskinesia | Phase 3 | Status: COMPLETED | Results posted: 2018-04-11